Fig. 4From: Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacyPHF Characterization, dosing methods, and PHF induced toxicity as measured via LDH. a Immunoblot showing enriched human PHF tau (PHF-1 staining) derived from an Alzheimer’s brain. b Neurons were exposed to PHF under one of four dosing paradigms. PHF was added alone, 24 h prior to antibody addition (PHF → Ab), together with antibody (PHF + Ab), or 24 h after antibody (Ab → PHF). Cells were washed with Neurobasal media between each step, and collection began 24 h after the last treatment applied. c In cells treated with 10 μg/ml PHF, LDH signal averaged 67 % above that of untreated controls (p < 0.01). 4E6 in the PHF + Ab and PHF → Ab paradigms significantly reduced LDH compared to PHF alone, and were comparable to untreated samples (11 and 15 % above control, p < 0.05), indicating that the antibody prevented toxicity. However, the Ab → PHF was not effective in reducing LDH signal (53 % above control) and showed no significant improvement over PHF alone samples. d All samples treated with 6B2 showed significantly higher levels of LDH relative to untreated controls (69, 59 and 79 % above control for the PHF + Ab, PHF → Ab, and Ab → PHF treatment groups respectively, p < 0.05). None of the treatments with 6B2 reduced LDH relative to PHF alone. e IgG was also not effective in preventing the increased LDH levels triggered by the addition of PHF. LDH in the PHF + Ab, PHF → Ab, and Ab → PHF groups was increased to 80, 43 and 61 % above control values (p < 0.05). None of the groups were significantly different from PHF alone. *: p < 0.05, **: p < 0.01, ***: p < 0.001Back to article page